Loading field map
Biochemical engineering is the branch of chemical engineering concerned with designing and operating processes that use living cells, or their components, to make useful products. It sits at the intersection of biology and chemical engineering: the raw materials and catalysts are biological, but the problems of scaling up, controlling, and purifying are engineering problems. The field’s central question is how to take a biological reaction that works in a laboratory flask—where conditions are mild, volumes are small, and contamination is manageable—and turn it into a reliable, safe, and economical industrial process that may operate in thousands of liters for weeks at a time.
Chemical engineering traditionally deals with reactors, separations, and process control. Biochemical engineering applies these same frameworks to systems where the "catalyst" is a living organism—typically a bacterium, yeast, fungus, or mammalian cell—or an isolated enzyme. This creates distinctive challenges. Living cells are not inert catalysts; they grow, mutate, consume nutrients, produce waste, and respond to their environment. They require sterile conditions because contaminating organisms will outcompete the desired one. They are sensitive to shear forces, temperature, pH, and dissolved oxygen. And their products are often made in low concentration in complex mixtures, making downstream purification difficult and expensive.
The field therefore has two intertwined concerns. The first is bioprocess engineering: the design and operation of bioreactors (fermenters) where cells grow and produce, including the supply of oxygen, the removal of heat, the control of pH, and the maintenance of sterility. The second is bioseparations: the sequence of steps—filtration, centrifugation, chromatography, crystallization—that recovers the desired product from the broth and purifies it to the required standard. A third, increasingly important concern is bioprocess development: the rational design of the biological system itself, through strain engineering or enzyme modification, so that it performs well under industrial conditions rather than merely in the laboratory.
The stakes are high because the products are essential. Biochemical engineering underpins the production of antibiotics, vaccines, insulin and other therapeutic proteins, enzymes for detergents and food processing, amino acids, vitamins, biofuels, bioplastics, and many other chemicals. The difference between a drug that costs pennies per dose and one that costs thousands is often not the biology but the engineering: yield, titer, and purification efficiency determine whether a process is viable.
The field emerged gradually from older practices of fermentation, which had been used for millennia to make beer, wine, bread, and cheese. These traditional processes were empirical and small-scale. The scientific understanding of fermentation as a biological process began in the nineteenth century with the work of Louis Pasteur, who showed that microorganisms were responsible. But the engineering discipline did not yet exist.
The decisive impetus came during the Second World War with the need to produce penicillin in large quantities. Penicillin had been discovered in 1928, but the original surface-culture method—growing the mold in shallow trays—could not meet wartime demand. A collaborative effort involving chemical engineers developed submerged fermentation: growing the mold in large stirred tanks with air bubbled through the liquid. This required solving problems of aeration, agitation, sterility, and pH control that had no precedent. The success of this effort established the template for modern bioprocessing and created the first generation of biochemical engineers.
In the decades that followed, the field expanded with the rise of the pharmaceutical industry. The 1970s and 1980s brought recombinant DNA technology, which allowed human proteins like insulin and growth hormone to be produced in bacteria. This created new challenges: the proteins were often produced inside cells and had to be released and refolded correctly; they were large, fragile molecules that could be damaged by the very processes used to purify them. The field responded by developing gentler separation methods and by engineering cells to secrete products into the medium.
A later shift came with the rise of monoclonal antibodies and other therapeutic proteins produced in mammalian cells. These cells grow slowly, require complex nutrients, and are easily damaged, but they can perform post-translational modifications—such as glycosylation—that bacteria cannot. The engineering challenge shifted toward developing serum-free media, fed-batch strategies, and single-use disposable bioreactors that reduced contamination risk and cleaning costs.
Biochemical engineering is not divided into rival schools in the way that some scientific fields are. It is better understood as a set of complementary approaches that address different parts of the same problem. These approaches coexist and often combine in practice.
The oldest approach is empirical: design a process by trial and error, guided by experience and rules of thumb. Early fermentation engineers scaled up from small vessels to large ones by maintaining geometric similarity and hoping that what worked at one scale would work at another. This approach often failed because the physics does not scale linearly: mixing time, oxygen transfer, and shear stress change with vessel size in complex ways. Nevertheless, the empirical tradition remains important because biological systems are so complex that first-principles prediction is often impossible. Many industrial processes are still developed by screening many conditions in small-scale experiments and then scaling up incrementally.
The most fundamental engineering approach applies the principles of transport phenomena—fluid mechanics, heat transfer, and mass transfer—to bioreactors. The key insight is that the performance of a bioreactor is often limited not by the biology but by the physical environment. Oxygen, for example, is poorly soluble in water; a high-density culture can consume oxygen faster than it can be supplied. The engineer must design impellers, spargers, and baffles to maximize gas-liquid mass transfer while minimizing the shear forces that damage cells. This approach uses dimensionless numbers, correlations, and computational fluid dynamics to predict mixing and transfer at scale. It is the core of traditional chemical engineering applied to biological systems, and it remains the foundation of bioreactor design.
A newer approach treats the biological organism itself as a system to be engineered. This includes metabolic engineering, which modifies the metabolic pathways of a cell to increase yield of a desired product or to enable it to use a cheaper feedstock; synthetic biology, which designs and constructs new biological parts and circuits; and systems biology, which uses genome-scale models to predict how a cell will behave under different conditions. This approach is fundamentally different from the transport phenomena approach because it works at the molecular and genetic level rather than the macroscopic level. It is also more recent, having become practical only with the development of genetic tools and computational modeling in the late twentieth and early twenty-first centuries.
The relationship between these approaches is complementary rather than competitive. A modern bioprocess is developed by combining them: metabolic engineering creates a strain that produces the desired compound efficiently; transport phenomena analysis designs the reactor that provides the right environment; and empirical screening optimizes the medium and operating conditions. The tension between them is practical rather than ideological. The biological approach can create strains that are theoretically superior but perform poorly in industrial reactors because they are sensitive to shear or oxygen limitation. The engineering approach can design reactors that are optimal for one strain but not another. The field's central skill is integrating these perspectives.
A more recent tendency is toward process intensification and platform technologies. Rather than designing a bespoke process for each new product, engineers seek generalizable systems that can be adapted quickly. Examples include continuous processing (as opposed to traditional batch operation), single-use disposable bioreactors, and modular purification systems. This approach is driven by economics: the cost of developing a new bioprocess is enormous, and any reduction in development time or increase in flexibility is valuable. It is not a separate intellectual tradition but rather a response to the commercial pressures of the biopharmaceutical industry.
The field today is shaped by several durable features. First, biopharmaceuticals—therapeutic proteins, antibodies, vaccines, and gene therapies—are the dominant application and the main driver of innovation. These products require extremely high purity and rigorous quality control, which has made bioprocess engineering a highly regulated discipline. The need to demonstrate that a process is consistent and reproducible has led to the development of process analytical technology (PAT), which uses real-time sensors and statistical methods to monitor and control bioprocesses.
Second, the rise of renewable chemicals and fuels has expanded the field beyond pharmaceuticals. Biofuels such as ethanol and butanol, bioplastics, and bio-based commodity chemicals are produced by fermentation of sugars or other biomass. These products are low-value and high-volume, which means the engineering challenge is entirely different from that of pharmaceuticals: the process must be extremely cheap and efficient, and the product must compete with petrochemicals on price. This has driven interest in using cheap feedstocks like lignocellulosic biomass, which requires pretreatment and enzymatic hydrolysis to release fermentable sugars.
Third, cell and gene therapies represent a new frontier. These therapies use living cells—often a patient's own cells, modified and expanded outside the body—as the product itself. The engineering challenge is to grow cells in large numbers while maintaining their identity and function, and to do so in a way that is safe and reproducible for each individual patient. This has led to the development of automated, closed-system bioreactors and to a focus on quality attributes that are biological rather than chemical.
Fourth, the field is increasingly computational and data-driven. Genome-scale metabolic models, machine learning, and digital twins of bioprocesses are used to predict strain behavior, optimize media, and guide scale-up. These tools do not replace experimental work but reduce the number of experiments needed and help interpret the vast amounts of data generated by modern sensors and analytics.
The field's boundaries are porous. It overlaps with biochemical engineering's parent discipline, chemical engineering, on the side of separations and reactor design; with microbiology and molecular biology on the side of the organism; and with food engineering, environmental engineering, and biomedical engineering in its applications. What distinguishes it is the consistent focus on the engineered process as the unit of analysis: the organism is a component of the process, and the process must be designed as a whole.
The enduring questions remain the same as they were in the penicillin era. How do you keep a living system alive and productive at industrial scale? How do you recover a fragile product from a complex mixture without destroying it? How do you do this reliably, safely, and economically? The answers have changed dramatically—from stirred tanks to single-use bioreactors, from trial-and-error to genome-scale models—but the questions define the field.